News

FDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.

A KPMG-Leavitt Partners report shows Medicare Advantage and Managed Medicaid are on slightly different trajectories. Expert Ash Shehata shares his predictions for both markets.

A Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.

In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.

A University of Phoenix College of Health Professions survey has surprising findings about RNs and health administrator views on healthcare hacking.

A new report from Radware has shocking findings about the healthcare industry’s low preparedness levels for cyberthreats. Here’s 4 ways to get ready.

The flu epidemic is taking a toll on the U.S. healthcare system. Here's how health insurers can curtail spending on flu care.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.

From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.

Patients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.

The high cost of specialty drugs continues to plague the healthcare industry. Here’s why.

Many providers are overlooking important steps that can help guide proper COPD treatment and therefore, reduce admissions and readmissions.

CMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know

Oncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.

How actively engaging millennials can help manage healthcare staffing challenges.

How did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.

Pending and recently approved treatment options for patients with chronic obstructive pulmonary disease range from biologics to a triple-drug inhaler.

FDA is taking its toughest stance yet on opioid-containing cough and cold medications for children.

FDA approved the first drug to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation.

Director of medication safety and quality for the American Society of Health-System Pharmacists shares how providers can better work with pharmacists to address the opioid epidemic.

Willis Towers Watson research finds a dramatic increase among employers seeking to differentiate their health and well-being programs for competitive advantage.

One major piece of interoperability is the expanded use of admission, discharge, and transfer (ADT) notifications across provider networks.

With influenza activity increasing sharply, here’s how healthcare executives can determine which health plan members are at risk for the flu.